Natixis is known for its innovation in structured products, particularly those using equity derivatives. It has also been part of the advance guard in green bond issuance. Now it has combined those skills to create a green structured product for wealthy individuals, while supporting a well-known biomedical research institute at the same time.
The product was structured by the equity derivatives team at Natixis Corporate and Investment Bank (CIB) and marketed by Natixis Wealth Management. Both are part of Groupe BPCE, whose Banque Populaire and Caisse d’Epargne retail networks make it France’s second-largest banking group.
